Skip to main content
Journal cover image

Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.

Publication ,  Journal Article
Goyal, A; Alexander, JH; Hafley, GE; Graham, SH; Mehta, RH; Mack, MJ; Wolf, RK; Cohn, LH; Kouchoukos, NT; Harrington, RA; Gennevois, D ...
Published in: Ann Thorac Surg
March 2007

BACKGROUND: Secondary prevention medications are beneficial after acute coronary syndromes, but these benefits are less clear after coronary artery bypass graft surgery. We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes. METHODS: Patients undergoing coronary artery bypass graft surgery in the PREVENT IV trial (n = 2970) were surveyed for use of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and lipid-lowering agents after hospital discharge and at 1 year. Patients were categorized based on their percentage use of indicated medications after hospital discharge. Cox modeling was used to determine the association between medication use categories and rates of death or myocardial infarction through 2 years after adjustment for clinical factors, the number of indicated medications, and treatment propensity. RESULTS: Rates of use of antiplatelet agents and lipid-lowering agents were high at discharge and at 1 year, but use of beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was suboptimal. There was a stepwise association between medication use at discharge and patient outcomes (p for trend = 0.014). Patients taking 50% or less of indicated medications at discharge had a significantly higher 2-year rate of death or myocardial infarction (8.0% versus 4.2%; adjusted hazard ratio, 1.69; 95% confidence interval, 1.12 to 2.55; p = 0.013) than those taking all indicated medications. CONCLUSIONS: Greater use of indicated secondary prevention medications after coronary artery bypass graft surgery is associated with a lower 2-year rate of death or myocardial infarction. These data underscore the importance of appropriate secondary prevention measures to improve long-term clinical outcomes after coronary artery bypass graft surgery.

Duke Scholars

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

March 2007

Volume

83

Issue

3

Start / End Page

993 / 1001

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Respiratory System
  • Proportional Hazards Models
  • Postoperative Care
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goyal, A., Alexander, J. H., Hafley, G. E., Graham, S. H., Mehta, R. H., Mack, M. J., … PREVENT IV Investigators, . (2007). Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg, 83(3), 993–1001. https://doi.org/10.1016/j.athoracsur.2006.10.046
Goyal, Abhinav, John H. Alexander, Gail E. Hafley, Stacy H. Graham, Rajendra H. Mehta, Michael J. Mack, Randall K. Wolf, et al. “Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.Ann Thorac Surg 83, no. 3 (March 2007): 993–1001. https://doi.org/10.1016/j.athoracsur.2006.10.046.
Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, et al. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 Mar;83(3):993–1001.
Goyal, Abhinav, et al. “Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.Ann Thorac Surg, vol. 83, no. 3, Mar. 2007, pp. 993–1001. Pubmed, doi:10.1016/j.athoracsur.2006.10.046.
Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED, PREVENT IV Investigators. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 Mar;83(3):993–1001.
Journal cover image

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

March 2007

Volume

83

Issue

3

Start / End Page

993 / 1001

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Respiratory System
  • Proportional Hazards Models
  • Postoperative Care
  • Platelet Aggregation Inhibitors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans